๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Mumbai
Clinical trial register · India

Clinical Trials in Mumbai

Every study on the ClinicalTrials.gov registry that lists a site in India and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 1125 matching records held by the registry are in this view. Synced 22 Sep 2026, 03:16 UTC
1125
Studies in scope
all four open statuses
610
Recruiting now
open to new participants
221
Lead sponsors
across recruiting studies
Top sites
New Delhi 334 Mumbai 259 Hyderabad 238 Bangalore 194 Pune 189
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca37 Tata Memorial Centre32 Tata Memorial Hospital22 Novo Nordisk A/S12 Eli Lilly and Company11
Site location
New Delhi334 Mumbai259 Hyderabad238 Bangalore194 Pune189
All 273 locations
Target enrolment
to
259 of 1125 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Indian sites
Start
Not yet open
To Determine the Difference in the Radiation Exposure, With Low Dose Protocols for Angiography
NCT06602583Coronary Arterial Disease (CAD)
Dr Bharat Singh Sambyal
Observational
60
Mumbai
2024-10-01
Active, closed
A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent ฮฒ-thalassemia, Using MRI Scans to Measure Iron Levels in the Body
NCT06421636Non-Transfusion Dependent Beta-Thalassemia (NTDT)
Regeneron Pharmaceuticals
Phase 2
19
Ahmedabad, Surat, Kochi, Mumbai, New Delhi, Jaipur
2024-09-30
Recruiting
Prospective Evaluation of 68Ga-FAPI PET in Biliary Cancers
NCT07337850Gall Bladder Cancer, Intrahepatic Cholangiocarcinoma (Icc)
Tata Memorial Centre
Observational
60
Mumbai
2024-09-25
Recruiting
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
NCT06528314NASH - Nonalcoholic Steatohepatitis, MASH - Metabolic Dysfunction-Associated Steatohepatitis
Akero Therapeutics, Inc
Phase 3
2,150
Hyderabad, Surat, Vadodara, Mysore, Thiruvananthapuram, Mumbai, Nagpur, Pune
2024-09-04
Recruiting
First in Human Multicenter Open Name Dose-increase, Consolidation Method to Study Safety Drug-level in Blood & Drug Metabolism Clinical Activity of Oral JBI-778 in Lung Cancer Patients With, Without Brain Metastasis IDH Mutated WHO Grade 3,4 Recurrent Glioma, Salivary Glands Tumor
NCT07755397NSCLC Patients With EGFR Activating Mutation, Adenoid Cystic Carcinoma Metastatic, Adenoid Cystic Carcinoma of the Head and Neck
Jubilant Therapeutics India Limited
Phase 1
30
Surat, Bangalore, Mumbai, Nashik, Thane, New Delhi
2024-08-26
By invitation
Efficacy and Safety of Picroliv in Patients With Non-Alcoholic Fatty Liver Disease
NCT07452744Non Alcholic Fatty Liver Disease
Bioagile Therapeutics Pvt. Ltd.
Not applicable
170
Chandigarh, Panjagutta, Chowk, Mumbai, Delhi, Vasant Kunj
2024-08-13
Recruiting
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
NCT06467357Biliary Tract Cancer
AstraZeneca
Phase 3
620
Dehradun, Delhi, Kanpur, Kolkata, Mumbai, Vadodara, Varanasi
2024-08-12
Recruiting
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
NCT06380751Advanced Breast Cancer
AstraZeneca
Phase 3
788
Delhi, Kolkata, Lucknow, Mumbai, Mysuru, Nagpur, Nashik, New Delhi
2024-08-01
By invitation
Long-term Safety and Tolerability of BHV-7000
NCT06443463Focal Epilepsy
Biohaven Therapeutics Ltd.
Phase 2
660
Hyderabad, Mangalore, Mumbai, Nagpur, New Delhi
2024-07-30
Recruiting
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
NCT06282575Biliary Tract Cancer
Jazz Pharmaceuticals
Phase 3
286
Belagavi, Mumbai, Nashik, Hyderabad, Varanasi, New Delhi
2024-07-19
Recruiting
Fibrosis Lessens After Metabolic Surgery
NCT06374875Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Non-Alcoholic Fatty Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis (MASH), Liver Fibrosis
The Cleveland Clinic
Phase 4
120
Indore, Mumbai
2024-07-11
Recruiting
Short Versus Long-term Levetiracetam in Brain Tumors
NCT06442748Seizures, Brain Tumors, Antiepileptics, Levetiracetam
Tata Memorial Centre
Phase 3
604
Udupi, Mumbai
2024-07-04
Recruiting
A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)
NCT06455449Polymyositis, Dermatomyositis
AstraZeneca
Phase 3
240
Ahmedabad, Dehradun, Delhi, Gurugram, Hyderabad, Kolkata, Lucknow, Mumbai
2024-06-20
Active, closed
Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma
NCT06356129Large B-cell Lymphoma
Celgene
Phase 3
850
Belagavi, Kochi, Mumbai, New Delhi, Howrah, New Town
2024-06-19
Active, closed
Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)
NCT06305754Non-small Cell Lung Cancer (NSCLC)
Merck Sharp & Dohme LLC
Phase 3
550
Gurugram, Mumbai, New Delhi
2024-06-11
Recruiting
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) โ‰ฅ50% (MK-1084-004/KANDLELIT-004)
NCT06345729Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC
Phase 3
600
Mumbai, New Delhi
2024-05-24
Recruiting
Postoperative Radiotherapy in Breast Cancer- Concurrent or Sequential With Chemotherapy
NCT06926543Invasive Breast Cancer, Stage III Breast Cancer, Stage IIB Breast Cancer
Dr. Tabassum Wadasadawala
Phase 3
858
Vishkhapatnam, Mumbai, New Chandigarh, Sangrur, Varanasi
2024-05-14
Active, closed
Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
NCT06309966Focal Epilepsy
Biohaven Therapeutics Ltd.
Phase 2/3
390
Hyderabad, Mangalore, Mumbai, Nagpur, New Delhi
2024-05-13
Recruiting
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
NCT06238622Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
Boehringer Ingelheim
Phase 3
1,700
Mumbai
2024-05-06
Active, closed
Endothelin Receptor Antagonism With Ambrisentan to Treat Hepatorenal Syndrome
NCT06256432Hepatorenal Syndrome, Liver Cirrhosis, Acute Kidney Injury, Ascites Hepatic
Noorik Biopharmaceuticals AG
Phase 2
54
Bangalore, Mumbai, New Delhi, Hyderabad, Kanpur, Lucknow
2024-04-17
Recruiting
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
NCT06312176Breast Neoplasms
Merck Sharp & Dohme LLC
Phase 3
1,200
Mumbai, New Delhi
2024-04-14
Recruiting
Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma
NCT05700149Nodal Marginal Zone Lymphoma
International Extranodal Lymphoma Study Group (IELSG)
Observational
300
Mumbai
2024-04-11
Recruiting
Study for Wait and Watch Suitable in Rectal Cancer
NCT06252142Rectal Neoplasms
Tata Memorial Centre
Observational
260
Mumbai
2024-04-01
Recruiting
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
NCT06256588Neoplasms, Head and Neck
GlaxoSmithKline
Phase 3
864
Mumbai, Pune, Bengaluru, Bhubaneswar, Gurgaon, Hyderabad, Nashik, Nehru Nagar Belagavi Karnataka 590010
2024-03-21
Active, closed
A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer
NCT06348199Non-small Cell Lung Cancer Stage IV
Samsung Bioepis Co., Ltd.
Phase 3
555
Bangalore, Bhubaneswar, Erandwane, Hyderabad, Jaipur, Mumbai, Sลซrat, Udaipur
2024-03-12
Rows per page Showing 101–125 of 259
Previous 3 4 5 6 7 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Indian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 22 September 2026. https://priyalifescience.com/clinical-trials-india/city/mumbai

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.